D. Western Therapeutics Institute, Inc.
Tokyo Stock Exchange 4576.T
D. Western Therapeutics Institute, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2023: -37.82%
-
D. Western Therapeutics Institute, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -15.92%, a -132.73% change year over year.
-
D. Western Therapeutics Institute, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -6.84%, a 39.27% change year over year.
-
D. Western Therapeutics Institute, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -11.27%, a -272.10% change year over year.
-
D. Western Therapeutics Institute, Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was 6.55%.
| Date | Return on Capital Employed (ROCE) | Interest Coverage Ratio | Debt to Equity Ratio | Return on Common Equity |
|---|
Don’t Miss A Beat
| CEO | Mr. Yuichi Hidaka |
| IPO Date | Oct. 23, 2009 |
| Location | Japan |
| Headquarters | CK21 Hirokoujifushimi Bldg. |
| Employees | 21 |
| Sector | Healthcare |
| Industries | |
D. Western Therapeutics Institute, Inc., a biotechnology company, focuses on discovery and development of various drugs. The company offers GLANATEC and GLA-ALPHA, an ophthalmic solution for the treatment of glaucoma/ocular hypertension; DW-1001, an ophthalmic drug; DWR-2206, a regenerative medicine cell-product for bullous keratopathy; and DW-1002, an ophthalmic surgical adjuvant for cataract surgeries, and ILM, ALC, ERM, and PVR membrane staining. It is also developing DW-5LBT, a lidocaine patch for neuropathic pain after shingles; K-321 to treat fuch endothelial corneal dystrophy which is in Phase III clinical trials; and H-1337, a multi-kinase inhibitor that has started Phase IIb clinical trials for the treatment of glaucoma/ocular hypertension. The company was founded in 1999 and is headquartered in Nagoya, Japan.
Past 5 years
StockViz Staff
February 11, 2025
Any question? Send us an email